Filing Details

Accession Number:
0001209191-22-023203
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-05 17:32:31
Reporting Period:
2022-04-01
Accepted Time:
2022-04-05 17:32:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1812364 Relay Therapeutics Inc. RLAY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1709772 A Donald Bergstrom C/O Relay Therapeutics, Inc.
399 Binney Street, 2Nd Floor
Cambridge MA 02139
President, R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-04-01 18,000 $4.12 112,304 No 4 M Direct
Common Stock Disposition 2022-04-01 18,000 $30.32 94,304 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-04-01 18,000 $0.00 18,000 $4.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
199,456 2028-04-09 No 4 M Direct
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
  2. Includes 91,200 shares underlying restricted stock units.
  3. This transaction was executed in multiple trades at prices ranging from $29.91 to $30.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.